doi:10.3969/j.issn.1004-583X.2024.11.015

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.11.015

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I11/1052

References 35

[1]	Mahtta D, Gupta A, Ramsey DJ, et al. Autoimmune rheumatic diseases and premature atherosclerotic cardiovascular disease: An analysis from the VITAL Registry[J]. Am J Med, 2020, 133(12):1424-1432. doi: 10.1016/j.amjmed.2020.05.026 pmid: 32598903
[2]	Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation[J]. Lupus Sci Med, 2019, 6(1):e000346.
[3]	Kurmann RD, Mankad R. Atherosclerotic heart disease in women with autoimmune rheumatologic inflammatory conditions[J]. Can J Cardiol, 2018, 34(4):381-389. doi: S0828-282X(18)30018-7 pmid: 29571422
[4]	Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus[J]. Rheum Dis Clin North Am, 2005, 31(2):329-354.
[5]	Katz G, Smilowitz NR, Blazer A, et al. Systemic lupus erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients[J]. Mayo Clin Proc, 2019, 94(8):1436-1443. doi: S0025-6196(19)30216-2 pmid: 31303426
[6]	Mendoza-Pinto C, Rojas-Villarraga A, Molano-González N, et al. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis[J]. Atherosclerosis, 2020, 297:55-63. doi: S0021-9150(20)30066-6 pmid: 32078830
[7]	Sciatti E, Cavazzana I, Vizzardi E, et al. Systemic lupus erythematosus and endothelial dysfunction: A close relationship[J]. Curr Rheumatol Rev, 2019, 15(3):177-188. doi: 10.2174/1573397115666181126105318 pmid: 30474532
[8]	Piranavan P, Perl A. Management of cardiovascular disease in patients with systemic lupus erythematosus[J]. Expert Opin Pharmacother, 2020, 21(13):1617-1628. doi: 10.1080/14656566.2020.1770227 pmid: 32511034
[9]	Ajeganova S, Gustafsson T, Lindberg L, et al. Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients[J]. Lupus Sci Med, 2020, 7(1):e000362.
[10]	陆玉琴, 赵信科, 冯明霞, 等. 高血压患者血清MMP-2, TIMP-2, Hcy, UA水平与颈动脉硬化的相关性[J]. 临床荟萃, 2020, 35(7):595-598.
[11]	Knight JS, Subramanian V, O’Dell AA, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice[J]. Ann Rheum Dis, 2015, 74(12):2199-2206. doi: 10.1136/annrheumdis-2014-205365 pmid: 25104775
[12]	Teixeira V, Tam LS. Novel insights in systemic lupus erythematosus and atherosclerosis[J]. Front Med (Lausanne), 2018, 4:262.
[13]	Polytarchou K, Varvarousis D, Manolis AS, et al. Cardiovascular disease in antiphospholipid syndrome[J]. Curr Vasc Pharmacol, 2020, 18(6):538-548. doi: 10.2174/1570161117666190830101341 pmid: 31530257
[14]	Hedar AM, Stradner MH, Roessler A, et al. Autoimmune rheumatic diseases and vascular function: The concept of autoimmune atherosclerosis[J]. J Clin Med, 2021, 10(19):4427.
[15]	Medeiros PBS, Salomão RG, Teixeira SR, et al. Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus[J]. Pediatr Rheumatol Online J, 2021, 19(1):35. doi: 10.1186/s12969-021-00513-5 pmid: 33743717
[16]	Ajeganova S, Hafström I, Frostegård J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: A case-control study over 10 years[J]. Lupus Sci Med, 2021, 8(1):e000454.
[17]	Ganjali S, Shirmohammadi L, Read MI, et al. High-density lipoprotein functionality in systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2020, 50(4):769-775.
[18]	王贞, 薛原, 林珺芳, 等. 高级氧化蛋白产物在系统性红斑狼疮早发动脉粥样硬化中的临床意义[J]. 中华风湿病学杂志, 2010, 14(6):404-407.
[19]	Giannelou M, Skarlis C, Stamouli A, et al. Atherosclerosis in SLE: A potential role for serum parathormone levels[J]. Lupus Sci Med, 2020, 7(1):e000393.
[20]	Sagar D, Gaddipati R, Ongstad EL, et al. LOX-1: A potential driver of cardiovascular risk in SLE patients[J]. PLoS One, 2020, 15(3):e0229184.
[21]	Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial[J]. Arthritis Care Res (Hoboken), 2011, 63(6):875-883. doi: 10.1002/acr.20440 pmid: 21309005
[22]	Castejon R, Castañeda A, Sollet A, et al. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity[J]. Lupus, 2016, 26(4):355-364.
[23]	Petri MA, Kiani AN, Post W, et al. Lupus atherosclerosis prevention study (LAPS)[J]. Ann Rheum Dis, 2011, 70(5):760-765. doi: 10.1136/ard.2010.136762 pmid: 21177297
[24]	Reiss AB, Arain HA, Kasselman LJ, et al. Human lupus plasma pro-atherogenic effects on cultured macrophages are not mitigated by statin therapy: A mechanistic LAPS substudy[J]. Medicina (Kaunas), 2019, 55(9):514.
[25]	Tselios K, Gladman DD, Su J, et al. Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study[J]. Arthritis Care Res (Hoboken), 2016, 68(10):1497-1504. doi: 10.1002/acr.22857 pmid: 26866934
[26]	Kostopoulou M, Nikolopoulos D, Parodis I, et al. Cardiovascular disease in systemic lupus erythematosus: Recent data on epidemiology, risk factors and prevention[J]. Curr Vasc Pharmacol, 2020, 18(6):549-565. doi: 10.2174/1570161118666191227101636 pmid: 31880245
[27]	Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus[J]. Am J Epidemiol, 2012, 176(8):708-719. doi: 10.1093/aje/kws130 pmid: 23024137
[28]	Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus[J]. Arthritis Res Ther, 2015, 17(1):277.
[29]	Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus[J]. J Rheumatol, 2017, 44(7):1032-1038. doi: 10.3899/jrheum.161351 pmid: 28507183
[30]	Leuven SIV, Wijk DFV, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis[J]. Atherosclerosis, 2010, 211(1):231-236. doi: 10.1016/j.atherosclerosis.2010.01.043 pmid: 20202636
[31]	Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years[J]. Rheumatol Int, 2012, 32(9):2701-2705. doi: 10.1007/s00296-011-2048-y pmid: 21792642
[32]	Roldan C, Joson J, Qualls C, et al. Premature aortic stiffness in systemic lupus erythematosus by transesophageal echocardiography[J]. Lupus, 2010, 19(14):1599-1605. doi: 10.1177/0961203310377088 pmid: 20813797
[33]	Oryoji K, Kiyohara C, Horiuchi T, et al. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A[J]. Mod Rheumatol, 2014, 24(1):86-92. doi: 10.3109/14397595.2013.852838 pmid: 24261763
[34]	Koulouri V, Koutsilieris M, Mavragani CP, et al. B cells and atherosclerosis in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2019, 15(4):417-429.
[35]	陈瞿, 葛风梅, 李昭, 等. 托法替布在系统性红斑狼疮小鼠早期动脉粥样硬化中的作用探讨[J]. 中华风湿病学杂志, 2024, 28(2):106-112.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(5): 475-480.
[2]	Qin Meijie, Tian Maolu, Yang Yuqi, Zha Yan, Yuan Jing. Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review [J]. Clinical Focus, 2022, 37(6): 544-547.
[3]	Gao Yuan;Meng Qinghua;Liu Haixia;Zhu Yueke. Abnormal liver function as the first symptom of systemic lupus erythematosus: analysis of 15 cases [J]. Clinical Focus, 2015, 30(7): 806-810.
[4]	HUANG Zhi-fang;LI Xin-lun;LI Hong-xia;LUN Li-de. Efficacy and safety of intravenous immunoglobulin in severe systemic lupus erythematosus [J]. Clinical Focus, 2014, 29(11): 1243-1245.
[5]	. [J]. Clinical Focus, 2014, 29(9): 1066-1067.
[6]	LI Hong-bo;ZHANG Jing-kun;WU Chao;WANG Ji;ZHANG Yu-jun;GAO Li-xia. Relationship of high mobility group protein 1,Toll-like receptors 4, vascular endothelial cell adhesion molecule-1 expression in lupus nephritis with dyslipidemia [J]. Clinical Focus, 2014, 29(8): 891-895.
[7]	. [J]. CLINICAL FOCUS, 2013, 28(10): 1179-1181.
[8]	WANG Zeng-ling;XING Guang-qun;LI Chun-mei. Level and significance of serum peptidylarginine deiminase type 4 in patients with systemic lupus erythematous [J]. Clinical Focus, 2013, 28(5): 515-518.
[9]	XU Xiao-ling;YU Xuan-hua;LI Yi-nong. Levels and clinical significance of B cell activating factor and interferon-α in systemic lupus erythematosus [J]. Clinical Focus, 2013, 28(5): 522-524532.
[10]	. [J]. Clinical Focus, 2012, 27(19): 1741-1742.
[11]	BAI Run-tao;GE Zhao-li;FENG Hong-ye;HAN Man-fu. Central nervous system impairment as an initial manifestation of patients with systemic lupus erythematosus [J]. Clinical Focus, 2012, 27(15): 1302-1305.
[12]	. [J]. Clinical Focus, 2012, 27(6): 527-528.
[13]	. [J]. CLINICAL FOCUS, 2011, 26(5): 435-436.
[14]	YU Xuan-hua;LI Yi-nong. Clinical cardiac imaging characteristics and influencing factors in 85 cases patients with systemic lupus erythematosus [J]. CLINICAL FOCUS, 2010, 25(13): 1119-1122.
[15]	. [J]. CLINICAL FOCUS, 2010, 25(13): 1175-0.